



## CAR T-cell Therapy for Lymphoma Research

Guest Editors:

**Dr. Dimitrios Tzachanis**

Division of Blood and Marrow  
Transplantation, University of  
California San Diego, La Jolla, CA  
92093, USA

**Dr. Ah-Reum Jeong**

Division of Blood and Marrow  
Transplantation, University of  
California San Diego, La Jolla, CA,  
USA

Deadline for manuscript  
submissions:

**closed (31 August 2023)**

### Message from the Guest Editors

Chimeric antigen receptor T-cell (CAR T-cell) therapy has revolutionized the treatment paradigm of various relapsed/refractory lymphomas that historically had limited treatment options and poor prognoses. The long-term progression-free survival after CAR T-cell therapy is 40 to 60% depending on the type of lymphoma, an astounding improvement from 10 to 20% in such a heavily pre-treated population. These advancements have led to the US FDA approving CAR T-cell therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma.

This Special Issue aims to improve our understanding of various aspects of CAR T-cell therapy for lymphomas.

Research areas may include (but are not limited to) the following: 1) advances in the construction of CAR T-cells, including off-the-shelf CAR T-cells and bispecific CAR T-cells; 2) expanding CAR T-cell therapy to non-approved indications; 3) combination therapy with different agents; 4) biomarkers for response and relapse; 5) prevention and treatment of related side effects; 6) disparity in access to CAR T-cell therapy; and 7) long-term complications and survivorship issues.





an Open Access Journal by MDPI

## Editor-in-Chief

**Prof. Dr. Samuel C. Mok**

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)